200 related articles for article (PubMed ID: 10466040)
1. Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: a potential mechanism of apoptotic epithelial turnover.
Bennett MW; O'Connell J; O'Sullivan GC; Roche D; Brady C; Collins JK; Shanahan F
Dis Esophagus; 1999; 12(2):90-8. PubMed ID: 10466040
[TBL] [Abstract][Full Text] [Related]
2. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
3. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.
Gratas C; Tohma Y; Barnas C; Taniere P; Hainaut P; Ohgaki H
Cancer Res; 1998 May; 58(10):2057-62. PubMed ID: 9605741
[TBL] [Abstract][Full Text] [Related]
5. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
[TBL] [Abstract][Full Text] [Related]
6. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover.
French LE; Hahne M; Viard I; Radlgruber G; Zanone R; Becker K; Müller C; Tschopp J
J Cell Biol; 1996 Apr; 133(2):335-43. PubMed ID: 8609166
[TBL] [Abstract][Full Text] [Related]
7. Fas ligand upregulation is an early event in colonic carcinogenesis.
Bennett MW; O'Connell J; Houston A; Kelly J; O'Sullivan GC; Collins JK; Shanahan F
J Clin Pathol; 2001 Aug; 54(8):598-604. PubMed ID: 11477113
[TBL] [Abstract][Full Text] [Related]
8. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
[TBL] [Abstract][Full Text] [Related]
9. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
[TBL] [Abstract][Full Text] [Related]
10. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas.
Kase S; Osaki M; Adachi H; Kaibara N; Ito H
Int J Oncol; 2002 Feb; 20(2):291-7. PubMed ID: 11788891
[TBL] [Abstract][Full Text] [Related]
11. Induction of Fas-mediated apoptosis in a human renal epithelial cell line by interferon-gamma: involvement of Fas-mediated apoptosis in acute renal rejection.
Akasaka Y; Ishikawa Y; Kato S; Ishii T; Masuda T; Fujita K; Yamada T; Kawamura S
Mod Pathol; 1998 Nov; 11(11):1107-14. PubMed ID: 9831209
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis in oral lichen planus.
Neppelberg E; Johannessen AC; Jonsson R
Eur J Oral Sci; 2001 Oct; 109(5):361-4. PubMed ID: 11695759
[TBL] [Abstract][Full Text] [Related]
13. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.
O'Connell J; Bennett MW; O'Sullivan GC; O'Callaghan J; Collins JK; Shanahan F
Clin Diagn Lab Immunol; 1999 Jul; 6(4):457-63. PubMed ID: 10391843
[TBL] [Abstract][Full Text] [Related]
14. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia.
Kitagawa M; Yamaguchi S; Takahashi M; Tanizawa T; Hirokawa K; Kamiyama R
Leukemia; 1998 Apr; 12(4):486-92. PubMed ID: 9557605
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
[TBL] [Abstract][Full Text] [Related]
16. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
O'Connell J; Bennett MW; O'Sullivan GC; Roche D; Kelly J; Collins JK; Shanahan F
J Pathol; 1998 Nov; 186(3):240-6. PubMed ID: 10211111
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer.
Sheehan KM; O'Donovan DG; Fitzmaurice G; O'Grady A; O'Donoghue DP; Sheahan K; Byrne MF; Conroy RM; Kay EW; Murray FE
Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):375-80. PubMed ID: 12655257
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
[TBL] [Abstract][Full Text] [Related]
19. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
[TBL] [Abstract][Full Text] [Related]
20. Expression of Fas-Fas ligand system associated with atresia in murine ovary.
Xu JP; Li X; Mori E; Sato E; Saito S; Guo MW; Mori T
Zygote; 1997 Nov; 5(4):321-7. PubMed ID: 9563680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
